Ovarian cancer biology and immunotherapy

International Reviews of Immunology

Volumn 33, Issue 5, 2014, Pages 428-440

  Latha, T Sree ^a   Panati, Kalpana ^b   Gowd, D Sravan Kumar ^a   Reddy, Madhava C ^a   Lomada, Dakshayani ^a  

^a YOGI VEMANA UNIVERSITY   (India)

^b Osmania University   (India)

Author keywords

DC vaccines; Experimental models; Immunotherapy; Ovarian cancer; Tumor microenvironment

Indexed keywords

CARCINOGEN; DENDRITIC CELL VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE;

CANCER IMMUNOTHERAPY; CANCER MORTALITY; EARLY DIAGNOSIS; EPITHELIUM TUMOR; EXPERIMENTAL MODEL; HUMAN; METASTASIS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PATHOPHYSIOLOGY; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; FEMALE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METABOLISM; OVARIAN NEOPLASMS; TRENDS; TUMOR ESCAPE;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84905862971     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2014.921161     Document Type: Review

References (93)

1. Siegel R, NaishadhamD, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
2. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA A Cancer J Clin 2010;60(5):277-300
3. Heintz AP,Odicino F,Maisonneuve P, et al. Carcinoma of the ovary. FIGO26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S161-S192
4. Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer 2010;1(6):277-290
5. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl JMed 2003;348(3):203-213
6. Cannon MJ, Goyne H, Stone PJ, Chiriva-Internati M. Dendritic cell vaccination against ovarian cancer-tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther 2011;11(4):441-445
7. Weiss NS, Homonchuk T, Young JL, Jr. Incidence of the histologic types of ovarian cancer: The U.S. Third National Cancer Survey, 1969-1971. Gynecol Oncol 1977;5(2):161-167
8. Nicosia SV.The aging ovary.Med Clin North Am 1987;71(1):1-9
9. Salazar H, Godwin AK, DalyMB, et al.Microscopic benign and invasivemalignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88(24):1810-1820
10. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971;2(7716):163
11. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35-51
12. Schildkraut JM, Schwingl PJ, Bastos E, et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88(4 Pt 1):554-559
13. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90(23):1774-1786
14. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. JNatl Cancer Inst 1999;91(17):1459-1467
15. Altinoz MA, Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenaseinhibitions as likelymechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 2004;51(4):239-247
16. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in theMillion Women Study. Lancet 2007;369(9574):1703-1710
17. Syed V, Ulinski G, Mok SC, et al. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal andmalignant human ovarian surface epithelial cells. Cancer Res 2001;61(18):6768-6776
18. Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2006;20(2):339-362
19. Gadducci A, Gargini A, Palla E, et al. Polycystic ovary syndrome and gynecological cancers: Is there a link? Gynecol Endocrinol 2005;20(4):200-208
20. Rosenberg L, Zhang Y, Coogan PF, et al. A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 2009;169(4):473-479
21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-264
22. Ben-Hur H, Gurevich P, Huszar M, et al. Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors. Eur J Gynaecol Oncol 2000;21(1): 53-57
23. Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998;95(8):4510-4515
24. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673): 245-252
25. Arpinati M, Chirumbolo G, Urbini B, et al. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2003;11(3-4):345-356
26. Lande R, Gilliet M. Plasmacytoid dendritic cells: Key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010;1183:89-103
27. Blasius A, Vermi W, Krug A, et al. A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. Blood 2004;103(11):4201-4206
28. Blasius AL, Cella M,Maldonado J, et al. Siglec-H is an IPC-specific receptor thatmodulates type I IFN secretion through DAP12. Blood 2006;107(6):2474-2476
29. Yoneyama H, Matsuno K, Zhang Y, et al. Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 2004;16(7):915-928
30. Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol 2005;174(1):244-251
31. Vanbervliet B, Bendriss-Vermare N, Massacrier C, et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J. Exp. Med 2003;198(5):823-830
32. Siegal FP, Kadowaki N, Shodell M, et al.The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284(5421):1835-1837
33. Ito T, YangM,Wang YH, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med 2007;204(1):105-115
34. Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008;28(6):870-880
35. Conrad C, Gilliet M. Plasmacytoid dendritic cells and regulatory T cells in the tumormicroenvironment: A dangerous liaison. Oncoimmunology 2013;2(5):e23887
36. Goubier A, Dubois B, Gheit H, et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 2008;29(3):464-475
37. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J. Exp. Med 2006;203(5):1153-1159
38. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010;117(2):366-372
39. Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumordraining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007;117(9):2570-2582
40. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells:more of the same or a division of labor? Immunity 2009;30(5):626-635
41. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389(6652):737-742
42. Jonuleit H, SchmittE.The regulatoryTcell family: Distinct subsets andtheir interrelations. J. Immunol 2003;171(12):6323-6327
43. Ramos RN, de Moraes CJ, Zelante B, Barbuto JA. What are the molecules involved in regulatory Tcells induction by dendritic cells in cancer? Clin Dev Immunol 2013;2013:806025
44. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102(51):18538-18543
45. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004;10(9):942-949
46. Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67(18):8900-8905
47. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057-1061
48. ZouW,Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med 2001;7(12):1339-1346
49. Folkman J. Angiogenesis in cancer, vascular,rheumatoid andotherdisease.Nat. Med 1995;1(1):27-31
50. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3(2):65-71
51. Frumovitz M, Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologicmalignancies. Gynecol Oncol 2007;104(3):768-778
52. Lokshin AE, Winans M, Landsittel D, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006;102(2):244-251
53. Davidson B,Goldberg I, Reich R, et al. AlphaV- and beta1-integrin subunits are commonly expressed inmalignant effusions fromovarian carcinoma patients. Gynecol Oncol 2003;90(2):248-257
54. Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10(15):5145-5150
55. Gavalas NG, Liontos M, Trachana SP, et al. Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int JMol Sci 2013;14(8):15885-15909
56. Li B, Lalani AS, Harding TC, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006;12(22):6808-6816
57. Lawicki S, Bedkowska GE, Gacuta-Szumarska E, SzmitkowskiM.The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res 2013;6(1):45
58. Auersperg N, Ota T, Mitchell GW. Early events in ovarian epithelial carcinogenesis: Progress and problems in experimental approaches. Int J Gynecol Cancer 2002;12(6):691-703
59. Daniel FB, Joyce NJ. 7,12-Dimethylbenz[a]anthracene-DNA adducts in Sprague-Dawley and Long-Evans female rats: The relationship of DNA adducts to mammary cancer. Carcinogenesis 1984;5(8):1021-1026
60. Nishida T, Sugiyama T,Kataoka A, et al.Histologic characterization of rat ovarian carcinoma induced by intraovarian insertion of a 7,12-dimethylbenz[a]anthracene-coated suture: Common epithelial tumors of the ovary in rats? Cancer 1998;83(5):965-970
61. Buters JT, Mahadevan B, Quintanilla-Martinez L, et al. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. Chem Res Toxicol 2002;15(9):1127-1135
62. Lohff JC, Christian PJ, Marion SL, Hoyer PB. Effect of duration of dosing on onset of ovarian failure in a chemical-inducedmouse model of perimenopause.Menopause 2006;13(3):482-488
63. Hoyer PB, Davis JR, Bedrnicek JB, et al. Ovarian neoplasm development by 7,12- dimethylbenz[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure. Gynecol Oncol 2009;112(3):610-615
64. Craig ZR, Davis JR,Marion SL, et al. 7,12-dimethylbenz[a]anthracene induces sertoli-leydig-cell tumors in the follicle-depleted ovaries ofmice treated with 4-vinylcyclohexene diepoxide. CompMed 2010;60(1):10-17
65. Orsulic S, Li Y, Soslow RA, et al. Induction of ovarian cancer by definedmultiple genetic changes in amouse model system. Cancer Cell 2002;1(1):53-62
66. Connolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63(6):1389-1397
67. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and Pten in the development ofmouse models of endometriosis and endometrioid ovarian cancer. Nat. Med 2005;11(1):63-70
68. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11(4):321-333
69. Quinn BA, Brake T, Hua X, et al. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PloS One 2009;4(12):e8404
70. Hunn J, RodriguezGC. Ovarian cancer: Etiology, risk factors, and epidemiology. ClinObstetGynecol 2012;55(1):3-23
71. Kinross KM, Montgomery KG, Kleinschmidt M, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 2012;122(2):553-557
72. Roby KF, Taylor CC, Sweetwood JP, et al.Development of a syngeneic mousemodel for events related to ovarian cancer. Carcinogenesis 2000;21(4):585-591
73. Zhang L, Yang N, Garcia JR, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002;161(6):2295-2309
74. Janat-Amsbury MM, Yockman JW, Anderson ML, et al. Comparison of ID8 MOSE and VEGFmodified ID8cell lines in an immunocompetent animal model for human ovarian cancer.Anticancer Res 2006;26(4B):2785-2789
75. Cho S, Sun Y, Soisson AP, et al. Characterization and evaluation of pre-clinical suitability of a syngeneic orthotopicmouse ovarian cancermodel. Anticancer Res 2013;33(4):1317-1324
76. Bellati F, Napoletano C, Ruscito I, et al. Past, present and future strategies of immunotherapy in gynecologicalmalignancies. CurrMolMed 2013;13(4):648-669
77. Morse MA, Deng Y, Coleman D, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5(6):1331-1338
78. Stiff PJ, Czerlanis C, Drakes ML. Dendritic cell immunotherapy in ovarian cancer. Expert Rev Anticancer Ther 2013;13(1):43-53
79. Santin AD, Bellone S, Underwood LJ, et al. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Ginecol 2002;54(2):133-144
80. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102-3108
81. Hernando JJ, Park TW, Kubler K, et al. Vaccinationwith autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51(1):45-52
82. Loveland BE, Zhao A,White S, et al.Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12(3 Pt 1):869-877
83. Hernando JJ, Park TW, Fischer HP, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007;8(5):451-454
84. Peethambaram PP, Melisko ME, Rinn KJ, et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res 2009;15(18):5937-5944
85. Chiang CL, Kandalaft LE, Tanyi J, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: From bench to bedside. Clin Cancer Res 2013;19(17):4801-4815
86. Kandalaft LE, Powell DJ, Jr., Chiang CL, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013;2(1):e22664
87. Defining the Role of CD4+CD25+ Immunoregulatory T-cells in the Treatment of Patients with Advanced Ovarian Cancer Who Receive Dendritic Cell Based Vaccine Therapies. Available at: Http://clinicaltrails.gov/ct2/show/ NCT00703105 [accessed October 2012
88. Vaccination of Patients with Ovarian Cancer with Dendritic Cell/Tumor Fusions with GM-CSF and Imiquimod. Available at: Http://clinicaltrails.gov/ct2/show/ NCT00799110 [accessed August 2013
89. Longuespee R, Boyon C, Desmons A, et al. Ovarian cancer molecular pathology. Cancer Metastasis Rev 2012;31(3-4):713-732
90. Chereau E, Lambaudie E, Houvenaeghel G. Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer. Int J Gynecol Cancer 2013;23(7):1326-1330
91. Zhang ZJ, Chen XH, Chang XH, et al. Human embryonic stem cells-a potential vaccine for ovarian cancer. Asian Pacific journal of cancer prevention. Asian Pac J Cancer Prev 2012;13(9):4295-4300
92. Kandalaft LE, Powell DJ, Jr., Singh N, Coukos G. Immunotherapy for ovarian cancer: What's next? Journal of clinical oncology. J Clin Oncol 2011;29(7):925-933
93. Kandalaft LE, Powell DJ, Jr., et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013;2(1):e22664